Roubaix Capital LLC Has $5.44 Million Position in Alpha Teknova, Inc. $TKNO

Roubaix Capital LLC boosted its holdings in shares of Alpha Teknova, Inc. (NASDAQ:TKNO) by 88.5% during the 1st quarter, Holdings Channel.com reports. The fund owned 1,882,355 shares of the company’s stock after purchasing an additional 883,823 shares during the period. Alpha Teknova comprises approximately 2.5% of Roubaix Capital LLC’s investment portfolio, making the stock its 15th biggest position. Roubaix Capital LLC’s holdings in Alpha Teknova were worth $5,440,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Susquehanna International Group LLP grew its position in Alpha Teknova by 25.0% in the third quarter. Susquehanna International Group LLP now owns 16,206 shares of the company’s stock worth $100,000 after acquiring an additional 3,246 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Alpha Teknova by 58.5% during the 3rd quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock valued at $58,000 after purchasing an additional 3,464 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Alpha Teknova by 123.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock valued at $40,000 after purchasing an additional 4,504 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in Alpha Teknova by 7.9% in the third quarter. Bridgeway Capital Management LLC now owns 80,900 shares of the company’s stock worth $501,000 after purchasing an additional 5,900 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Alpha Teknova in the second quarter worth $29,000. 13.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Teknova in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

Alpha Teknova Price Performance

NASDAQ TKNO opened at $5.42 on Friday. The stock has a 50-day simple moving average of $4.81 and a 200 day simple moving average of $3.60. Alpha Teknova, Inc. has a twelve month low of $1.91 and a twelve month high of $6.68. The stock has a market capitalization of $290.59 million, a PE ratio of -16.94 and a beta of 0.62. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.60 and a current ratio of 4.59.

Alpha Teknova (NASDAQ:TKNO) last released its earnings results on Wednesday, May 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $11.08 million for the quarter, compared to analyst estimates of $10.23 million. Alpha Teknova had a negative return on equity of 24.32% and a negative net margin of 41.07%.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.